Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Company Profiles

Set Alert for Emerging Company Profiles

Ellipses Accelerates Cancer Treatment R&D With ‘Unique’ Business Model

Emerging Company Profile: The UK biotech is working to expedite its portfolio of acquired drug candidates for cancer through the clinic before out-licensing to big pharma in a bid to bring patients the treatments they need sooner rather than later.

Emerging Company Profile Cancer

SFA Therapeutics Harnesses Power Of Bacterial Metabolites To Treat Inflammatory Disease

Emerging Company Profile: The US biotech is advancing its lead candidate into a Phase Ib psoriasis trial as it works to validate its bacterial metabolite-based drug platform, which exemplifies a new generation of microbiome technology.

Emerging Company Profile Companies

Medannex Advances First ANAX1 Antagonist With Modular Cancer Trial Approach

Emerging Company Profile: The Scottish biotech is the only firm targeting the ANAX1 protein with plans to initiate a modular Phase I trial that could look at multiple tumor types before expanding to the autoimmune space.

Emerging Company Profile Companies

Tetraneuron Touts Its Multifactorial Gene Therapy Solution For Alzheimer’s

Emerging Company Profile: The biotech plans to enter the clinic next year with a gene therapy targeting the E2F4 protein in the hopes of halting Alzheimer’s disease progression and restoring lost function.

Emerging Company Profile Neurology

Acousia To Refresh Stagnant Hearing Loss Space With New Potassium Channel Approach

The German biotech plans to prevent chemotherapy-induced hearing loss and treat chronic hearing loss by targeting a potassium channel in the ear’s sensory hair cells as it tackles a widespread but side-lined area.

Emerging Company Profile Companies

Ordaõs Looks To Unlock The Therapeutic Promise Of Mini-Proteins

Emerging Company Profile: Mini-proteins offer some of the capabilities of small molecules and antibodies with fewer limitations, Ordaõs claims. The biotech wants to lead a paradigm shift from discovery to design.

Emerging Company Profile Business Strategies

NMD Pharma Nears Validation For ClC-1 Inhibition With Lead Program In Myasthenia Gravis

Emerging Company Profile: The Danish firm has achieved proof-of-mechanism for its first-in-class CIC-1 inhibitor asset in myasthenia gravis as it advances a pipeline of transformative therapies for rare neuromuscular disorders.

Emerging Company Profile Companies

AviadoBio Targets Rare Form Of Dementia With Gene Therapy

The UK biotech hopes to address a fast-progressing form of dementia that affects people earlier in life with a supplemental gene therapy delivered directly to the brain’s information centre.

Emerging Company Profile Companies

Peptilogics’ AI Peptide Platform Could Help Address Orthopedic Unmet Need

Emerging Company Profile: US firm Peptilogics is advancing through the clinic with its lead orthopedic anti-infective drug candidate based on an AI platform that utilizes algorithms to improve peptide design.

Emerging Company Profile Orthopedics

Step Pharma Aims To Become CTP Synthase 1 Leader, Starting With Aggressive Lymphoma

Emerging Company Profile: The French firm, which is developing the lead CTP synthase 1 inhibitor in the pipeline, plans to address a range of cancers with its highly selective approach.

Emerging Company Profile Companies

AdipoPharma Targets Root Cause Of Diabetes With First ‘Adipeutic’ Drug Candidate

Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.

Emerging Company Profile Metabolic Disorders

PanTher Reimagines Cardiology Interventions As Precision Oncology Platform

Emerging company profile: The US biotech is wrapping up a Phase I trial for its lead pancreatic cancer program at the end of this year and hopes to expand its precision drug-device combination platform to a range of other solid tumors.

Emerging Company Profile Cancer
See All
UsernamePublicRestriction

Register